Execs On The Move: New Chiefs At Neurotech, Photocure
An early investor in the Australian neurostimulation and neuro-diagnostic company Neurotech International is now the firm's CEO. And Photocure, focused on photodynamic technology for bladder cancer, hired a new chief executive from Ablynx.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.